三友医疗（688085）：国际化表现亮眼，国内业务逐步恢复

Investment Rating - The investment rating for the company is "Buy" with a previous rating of "Buy" as well [1] Core Views - The company reported a revenue of 391 million RMB for the first three quarters of 2025, representing a year-on-year growth of 17.65%. The net profit attributable to the parent company was 61.98 million RMB, showing a significant increase of 623.19% year-on-year [4] - The company is experiencing rapid growth in its ultrasonic bone knife business and has begun to make breakthroughs in its international operations, leading to a positive outlook for future development [4][6] Summary by Relevant Sections Financial Performance - The company adjusted its profit forecast, expecting net profits for 2025-2027 to be 115 million, 179 million, and 259 million RMB respectively, with corresponding EPS of 0.34, 0.54, and 0.78 RMB. The current stock price corresponds to PE ratios of 55.7, 35.7, and 24.7 times for the respective years [6][8] - The company’s revenue for Q3 was 142 million RMB, a year-on-year increase of 17.44%, with a net profit of 25.38 million RMB, up 268.13% year-on-year [9] Business Segments - The ultrasonic bone knife business showed impressive performance, with revenue of 115 million RMB in the first three quarters, a growth of 52.21% year-on-year. The company has completed its performance commitments for 2025 [9] - The international business is progressing rapidly, with the French subsidiary Implanet achieving revenue of 2.92 million euros in Q3, a growth of 26.37%, and the US market contributing 1.06 million euros, up 22.21% [9] Future Outlook - The company’s innovative products are entering a harvest phase, with recent approvals for new products enhancing its domestic product line. This is expected to stabilize domestic business growth [9]